NM_002047.4:c.2121A>C

Variant names:

• chr7-30633761-A-C
• rs1554340999
• NM_002047.4:c.2121A>C

Variant summary

Our verdict is Uncertain significance. Variant got 0 ACMG points: 2P and 2B. PM2 BP4_Moderate

The NM_002047.4(GARS1):​c.2121A>C​(p.Gln707His) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a benign outcome for this variant. 15/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★).

• Frequency: Genomes: not found (cov: 31)
• Consequence: GARS1 NM_002047.4 missense
• Clinical Significance: Uncertain significance criteria provided, single submitter U:1
• Conservation: PhyloP100: -0.875

Genes affected

GARS1 (HGNC:4162): (glycyl-tRNA synthetase 1) This gene encodes glycyl-tRNA synthetase, one of the aminoacyl-tRNA synthetases that charge tRNAs with their cognate amino acids. The encoded enzyme is an (alpha)2 dimer which belongs to the class II family of tRNA synthetases. It has been shown to be a target of autoantibodies in the human autoimmune diseases, polymyositis or dermatomyositis. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Oct 2015]

ACMG classification

Verdict is Uncertain_significance. Variant got 0 ACMG points.

• PM2: Very rare variant in population databases, with high coverage
• BP4: Computational evidence support a benign effect (MetaRNN=0.10170412).

Transcripts

RefSeq

Gene	Transcript	HGVSc	HGVSp	Effect	Exon rank	MANE	Protein	UniProt
GARS1	NM_002047.4	c.2121A>C	p.Gln707His	missense_variant	Exon 17 of 17	ENST00000389266.8	NP_002038.2
GARS1	NM_001316772.1	c.1959A>C	p.Gln653His	missense_variant	Exon 17 of 17		NP_001303701.1

Ensembl

Gene	Transcript	HGVSc	HGVSp	Effect	Exon rank	TSL	MANE	Protein	Appris	UniProt
GARS1	ENST00000389266.8	c.2121A>C	p.Gln707His	missense_variant	Exon 17 of 17	1	NM_002047.4	ENSP00000373918.3
GARS1	ENST00000675651.1	c.2139A>C	p.Gln713His	missense_variant	Exon 17 of 17			ENSP00000502513.1
GARS1	ENST00000675810.1	c.2019A>C	p.Gln673His	missense_variant	Exon 16 of 16			ENSP00000502743.1
GARS1	ENST00000675693.1	c.1953A>C	p.Gln651His	missense_variant	Exon 18 of 18			ENSP00000502174.1
GARS1	ENST00000675051.1	c.1920A>C	p.Gln640His	missense_variant	Exon 17 of 17			ENSP00000502296.1
GARS1	ENST00000674815.1	c.1752A>C	p.Gln584His	missense_variant	Exon 17 of 17			ENSP00000502799.1
GARS1	ENST00000674851.1	c.1752A>C	p.Gln584His	missense_variant	Exon 18 of 18			ENSP00000502451.1
GARS1	ENST00000444666.6	n.*542A>C		non_coding_transcript_exon_variant	Exon 18 of 18	3		ENSP00000415447.2
GARS1	ENST00000674616.1	n.*1835A>C		non_coding_transcript_exon_variant	Exon 18 of 18			ENSP00000502408.1
GARS1	ENST00000674643.1	n.*1926A>C		non_coding_transcript_exon_variant	Exon 17 of 17			ENSP00000501636.1
GARS1	ENST00000674737.1	n.*1459A>C		non_coding_transcript_exon_variant	Exon 18 of 18			ENSP00000502464.1
GARS1	ENST00000674807.1	n.*394A>C		non_coding_transcript_exon_variant	Exon 16 of 16			ENSP00000502814.1
GARS1	ENST00000675529.1	n.*1991A>C		non_coding_transcript_exon_variant	Exon 18 of 18			ENSP00000501655.1
GARS1	ENST00000675859.1	n.*300A>C		non_coding_transcript_exon_variant	Exon 15 of 15			ENSP00000502033.1
GARS1	ENST00000676088.1	n.*2063A>C		non_coding_transcript_exon_variant	Exon 19 of 19			ENSP00000501884.1
GARS1	ENST00000676140.1	n.*1066A>C		non_coding_transcript_exon_variant	Exon 17 of 17			ENSP00000502571.1
GARS1	ENST00000676164.1	n.*1572A>C		non_coding_transcript_exon_variant	Exon 17 of 17			ENSP00000501986.1
GARS1	ENST00000676210.1	n.*1410A>C		non_coding_transcript_exon_variant	Exon 18 of 18			ENSP00000502373.1
GARS1	ENST00000676259.1	n.*1553A>C		non_coding_transcript_exon_variant	Exon 17 of 17			ENSP00000501980.1
GARS1	ENST00000676403.1	n.*206A>C		non_coding_transcript_exon_variant	Exon 16 of 16			ENSP00000502681.1
GARS1	ENST00000444666.6	n.*542A>C		3_prime_UTR_variant	Exon 18 of 18	3		ENSP00000415447.2
GARS1	ENST00000674616.1	n.*1835A>C		3_prime_UTR_variant	Exon 18 of 18			ENSP00000502408.1
GARS1	ENST00000674643.1	n.*1926A>C		3_prime_UTR_variant	Exon 17 of 17			ENSP00000501636.1
GARS1	ENST00000674737.1	n.*1459A>C		3_prime_UTR_variant	Exon 18 of 18			ENSP00000502464.1
GARS1	ENST00000674807.1	n.*394A>C		3_prime_UTR_variant	Exon 16 of 16			ENSP00000502814.1
GARS1	ENST00000675529.1	n.*1991A>C		3_prime_UTR_variant	Exon 18 of 18			ENSP00000501655.1
GARS1	ENST00000675859.1	n.*300A>C		3_prime_UTR_variant	Exon 15 of 15			ENSP00000502033.1
GARS1	ENST00000676088.1	n.*2063A>C		3_prime_UTR_variant	Exon 19 of 19			ENSP00000501884.1
GARS1	ENST00000676140.1	n.*1066A>C		3_prime_UTR_variant	Exon 17 of 17			ENSP00000502571.1
GARS1	ENST00000676164.1	n.*1572A>C		3_prime_UTR_variant	Exon 17 of 17			ENSP00000501986.1
GARS1	ENST00000676210.1	n.*1410A>C		3_prime_UTR_variant	Exon 18 of 18			ENSP00000502373.1
GARS1	ENST00000676259.1	n.*1553A>C		3_prime_UTR_variant	Exon 17 of 17			ENSP00000501980.1
GARS1	ENST00000676403.1	n.*206A>C		3_prime_UTR_variant	Exon 16 of 16			ENSP00000502681.1

Frequencies

GnomAD3 genomes Cov.: 31

GnomAD4 exome Cov.: 41

GnomAD4 genome Cov.: 31

ClinVar

Significance: Uncertain significance

Submissions summary: Uncertain:1

Revision: criteria provided, single submitter

Submissions by phenotype

Charcot-Marie-Tooth disease type 2 Uncertain:1

Dec 13, 2017

Labcorp Genetics (formerly Invitae), Labcorp

Significance: Uncertain significance

Review Status: criteria provided, single submitter

Collection Method: clinical testing

This sequence change replaces glutamine with histidine at codon 707 of the GARS protein (p.Gln707His). The glutamine residue is weakly conserved and there is a small physicochemical difference between glutamine and histidine. This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals with GARS-related disease. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -

Computational scores

Source: dbNSFP v4.3

Name	Calibrated prediction	Score	Prediction
AlphaMissense	Benign	0.12
BayesDel_addAF	Benign	-0.097	T
BayesDel_noAF	Benign	-0.38
CADD	Benign	1.7
DANN	Benign	0.97
DEOGEN2	Benign	0.11	T
Eigen	Benign	-0.80
Eigen_PC	Benign	-0.77
FATHMM_MKL	Benign	0.24	N
LIST_S2	Uncertain	0.86	D
M_CAP	Benign	0.052	D
MetaRNN	Benign	0.10	T
MetaSVM	Benign	-0.85	T
PrimateAI	Benign	0.23	T
PROVEAN	Benign	-0.52	N
REVEL	Benign	0.17
Sift	Benign	0.10	T
Sift4G	Benign	0.11	T
Polyphen		0.0	B
Vest4		0.27
MutPred		0.46		Gain of catalytic residue at L709 (P = 0.0558);
MVP		0.50
MPC		0.58
ClinPred		0.24	T
GERP RS		-0.61
Varity_R		0.081
gMVP		0.49

Splicing

Name	Calibrated prediction	Score	Prediction
SpliceAI score (max)		0.0		Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Other links and lift over

dbSNP: rs1554340999; hg19: chr7-30673377;